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Abstract
Background: CC-chemokine receptor seven (CCR7), a G-protein coupled receptor normally facilitating immune cells
lymphatic homing, has recently been identified on several cancer cells in promoting invasion and lymphatic specific
metastasis by mimicking normal leukocytes. As tyrosine kinase inhibitors for metastatic renal cell carcinoma (mRCC)
mostly emphasized on vascular inhibition, whether the CCR7 expressing tumor cells with potential lymphatic
invasion function could have an impact on mRCC patient’s drug response and survival, was unknown.
Methods: In this study, in a clinical aspect, we retrospectively investigated the prognostic and predictive impact of
tumoral CCR7 expression in 110 mRCC patients treated with sunitinib and sorafenib, and its correlation with pre- or
post-administration lymphatic involvement. Immunohistochemistry on tissue microarrays were conducted for CCR7
expression evaluation.
Results: Kaplan-Meier and univariate analyses suggested high tumoral CCR7 expression as an adverse prognosticator
for mRCC patients’ overall survival (OS), which was further confirmed in the multivariate analyses (P = 0.002, P = 0.003
for bootstrap). This molecule could be combined with Heng’s risk model for better patient OS prediction. High tumoral
CCR7 expression was also an independent dismal predictor for patients’ progression free survival (PFS) (P = 0.010, P = 0.
013 for bootstrap), and correlated with poorer best drug response. Moreover, a possible correlation of CCR7 high
expression and patients’ baseline and post-administration lymph node metastasis was found.
Conclusions: High tumoral CCR7 expression correlated with potential lymphatic involvement and poor prognosis of
mRCC patients treated with tyrosine kinase inhibitors. Further external validations and basic researches were needed to
confirm these results.
Keywords: Metastatic renal cell carcinoma, CC-chemokine receptor 7, Overall survival, Progression free survival,
Lymphatic invasion
Background
For patients with metastatic renal cell carcinoma
(mRCC), therapeutic options have expanded significantly
these years, since vascular endothelial growth factor
(VEGF)-targeted tyrosine kinase inhibitor (TKI) drugs
such as sunitinib and pazopanib have been established as
first-line therapy [1]. Several clinical based prognostic
models, for example the Heng’s risk criteria, have also
achieved remarkable progress in mRCC patient survival
prediction [2]. However, the objective response rates
(ORRs) for most first-line TKI drugs were only around
30% [3], and the lack of validated molecular biomarkers
impeded their personalized approach [4]. This was in con-
trast to many other tumor types, in which protein expres-
sion and mutation were used as basic accesses for drugs
response and patient survival prediction [5, 6].
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CC-chemokine receptor 7 (CCR7), a G-protein coupled
receptor (GPCR) mostly expressed on immune cells, was
initially regarded as an important regulator facilitating leu-
kocytes homing to the lymphatic structures, where its two
ligands CC-chemokine ligand 19 (CCL19) and CCL21 are
constitutively expressed [7]. However, in recent years, ab-
errant high CCR7 expression has also been identified on
several tumor types, linking to a potential invasive pheno-
type [8]. It has been suggested that CCR7 positive tumor
cells could mimic the normal lymphocyte homing func-
tion and interact with lymph vessels, leading to subse-
quent lymph node specific metastasis [9].
Lymphatic and hematogenous disseminations were
two regular metastasis pathways for malignancy. For
mRCC, although the most common metastatic site was
the lung, possibly via a hematogenous approach, local or
distant lymph node involvement at diagnosis was not
rare [10]. Patient receiving TKIs could also develop new
lymph node metastasis during the treatment, leading to
a progressive disease (PD). Several theories of TKI drug
resistance emphasized an increase of tumor cell invasive-
ness after drug administration [11]. These processes
mostly accompanied with tumor cell migration and
matrix metalloproteinase-9 (MMP-9) mediated extracel-
lular matrix degradation [12], which was similar to the
CCR7 mediated lymph vessel intravasation process [8].
As VEGF targeted therapies mostly focused on blood
vessels inhibition, whether they could enhance the possi-
bility of mRCC metastasis through other pathways, such
as CCR7 mediated lymph vessel invasion and therapy re-
sistance, was not known.
Thus, here through immunohistochemistry (IHC), we
retrospectively evaluated the CCR7 expression in 110
primary tumor specimens of mRCC patients treated with
sunitinib and sorafenib. The result suggested a positive
correlation of CCR7 expression with patient baseline
lymph node metastasis and TKI drugs response. CCR7
high expression could predict a poorer overall survival




We initially screened a total of 138 mRCC patients
treated with sunitinib or sorafenib between March 2005
and June 2014 at the Department of Urology, Zhongshan
Hospital, Fudan University. The inclusion criteria were:
pathologically proven RCC patient with metastatic le-
sion, treated with sunitinib or sorafenib at first without
further second-line treatment, had enough Formalin
Fixed Paraffin Embedded (FFPE) specimens, and had de-
tailed laboratorial, imaging and survival information. Pa-
tients who had former malignant history, received
metastasectomy or those with tumor necrosis area
>80%, unavailable data were excluded. At last, 28 pa-
tients were excluded and 110 patients were selected for
the study, in which three were excluded from PFS ana-
lysis for incomplete drug response information. This
study was approved by the Clinical Research Ethics
Committee of Zhongshan Hospital, Fudan University
(Shanghai, China) (B2015-030).
Patients’ OS was defined as the time from therapy ini-
tiation to the time of death, or was censored at the last
follow-up. PFS was calculated from the time of therapy
initiation to the time of progression, according to the
RECIST 1.1 criteria [13], or was censored at the last
follow-up. All data were collected retrospectively from
medical records and electronic databases using uniform
database templates, and the last follow-up time was
December 2015. According to the 2014 EAU guidelines
[14] and 2012 ISUP consensus [15], two urologic pathol-
ogists (Yuan J. and Jun H.) independently reviewed all
the H & E slides of patient samples and confirmed the
RCC diagnosis and Fuhrman grade classification. Initial
stage at diagnosis was reclassified based on the 2010
AJCC TNM classification [10]. Heng’s risk model was
applied as previously reported [2].
Tissue microarray and immunohistochemistry
Two representative tumor cores 3 mm in diameter from
each sample were selected for tissue micro array (TMA)
construction. Anti-CCR7 antibody (ab32527, Abcam, di-
luted 1/1000) and Dako EnVision Detection System were
applied in the immunohistochemistry procedure [16].
Through western blot in RCC cell lines, the specificity of
antibody was confirmed. Negative control was per-
formed without applying primary antibody. Olympus
CDD camera, Nikon eclipse Ti-s microscope (×200 mag-
nification) and NIS-Elements F3.2 software were used to
record the staining results. Using Image-Pro Plus version
6.0 software (Media Cybernetics Inc., USA), an inte-
grated optical density (IOD) score could be calculated
for each scan. Two urologists unaware of the patients’
clinical data evaluated these slides. Each person took
three independent shots with the strongest staining for
each core, and the IOD mean of each patient’s two cores
(six scans) were calculated. Kappa value was calculated
for evaluating inter-observer agreement.
Statistical analysis
Univariate analysis was carried out to explore the prog-
nostic and predictive value of continuous CCR7 IOD
score. The smooth estimates of hazard ratio (HR) of
IOD on patient survival were displayed using R software,
“phenoTest” package [17]. For clinical usage, we dichot-
omized the IOD into high/low expression through mini-
mum p value method using x-tile software [18], and
because the p values obtained might be overestimated,
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they were corrected using the formula proposed by Alt-
man and colleagues [19]. The smooth HR curves after
dichotomizing were illustrated through R software,
“smoothHR” package [20]. After this, χ2 test, Fisher’s
exact method and Cochran-Mantel-Haenszel χ2 test
were applied for assessing the relationship between
CCR7 expression and patients’ clinicopathological pa-
rameters. Kaplan–Meier, univariate and subsequent
multivariate analysis were performed, in which 1000
bootstrap resamples was used for reducing overfitting
bias. Finally, time dependent receiver operating charac-
teristic (ROC) analysis was done to analyze the adding
prognostic value of CCR7 expression to the Heng’s risk
model. GraphPad Prism 6 (GraphPad Software Inc.,
USA), SPSS 21.0 (SPSS Inc., USA), X-tile 3.6.1 (Robert L
Camp, USA) and R software 3.1.2 (R Foundation for
Statistical Computing, Austria) were used in these
procedures. A two-sided P-value < 0.05 was regarded as
statistically significant.
Results
CCR7 staining and cut off point choosing
CCR7 expression in the RCC sample was variable, and
mostly on the membrane and cytoplasm of tumor cells
(Additional file 1: Figure S1A and B). Its expression in
peritumoral tissue was relatively low (Additional file 1:
Figure S1C). Inter-observer agreement was acceptable
according to the kappa value 0.745, thus the CCR7 IOD
means from the two observers were again averaged as
the final IOD, and the distributions were 73–584 for
range; 238 ± 97 for mean and SD; 223 (173–287) for me-
dian and IQR.
In order to select an appropriate cut off value for clinical
usage, first we performed a univariate analysis using the
continuous CCR7 IOD score (Additional file 2: Table S1).
Result suggested CCR7 as a significant adverse prognostic
marker for mRCC patients’ OS and PFS (P < 0.001 for
Table 1 Clinical characteristics of patients according to tumoral
CCR7 expression
Characteristics Patients Tumoral CCR7 expression
n % low high P-value
No. of patients 110 100 53 57
Age, years, mean (SD) 57.5 (11.9)
Men 79 71.8
ECOG PS 0.198c
0 81 73.6 42 39





Clear cell 88 80.0 46 42
Non-clear cell type 22 20.0 7 15
Papillary 15 13.6
Chromophobe 2 1.8
Collecting duct 2 1.8
Unclassified 3 2.7
Fuhrman grade (7 excluded) 0.147d
1 2 1.8 2 0
2 53 48.2 28 25
3 41 37.3 18 23
4 7 6.4 5 2
TNM stage at initial diagnosis 0.004c
I-III 51 46.4 32 19
IV 59 53.6 21 38




Lymph node 29 26.4
Adrenal gland 8 7.3
Brain and others 15 13.6
Lymph node involvementa 0.031c
No 81 73.6 44 37
Yes 29 26.4 9 20
No. of metastatic sitesa 0.070c
1 76 69.1 41 35
≥ 2 34 30.9 12 22
Tyrosine kinase inhibitors 0.254c
Sunitinib 73 66.4 38 35
Sorafenib 37 33.6 15 22
Heng’s risk group 0.271d
Table 1 Clinical characteristics of patients according to tumoral
CCR7 expression (Continued)
Favorable 22 20 12 10
Intermediate 60 54.5 30 30
Poor 28 25.5 11 17
Best response (3 not assessable) <0.001d
Partial response 27 25.2 18 9
Stable disease for ≥3 months 57 53.3 30 27
Progressive diseaseb 23 21.5 2 21
Bold data means statistical significant (P<0.05)
SD standard deviation, ECOG PS Eastern Cooperative Oncology Group
performance status
P-value < 0.05 was regarded as statistically significant
aAt the time initializing tyrosine kinase inhibitors
bIncluding stable disease for <3 months
cχ2 test or Fisher’s exact test
dCochran-Mantel-Haenszel χ2 test
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both). Smooth HR curve demonstrated the adding risk of
1 per IOD on patient survival (Additional file 1: Figure
S1D and F). Then, through minimum p value method
using log rank test, IOD = 215 was chosen as the cut off
point (P < 0.001 for both), and the p values were still
significant after being corrected (OS, P < 0.001, PFS, P =
0.001). The smooth HR curve also displayed significant
and stable prognostic differences after dichotomizing
(Additional file 1: Figure S1E and G).
Patient baseline characteristics and its association with
dichotomous CCR7 expression
The 110 patients’ baseline clinical characteristics were
shown in Table 1. All patients were East Asian. The
medium age at TKIs initiation was 59 years old
(range 14–78). All patients have received radical, par-
tial or cytoreductive nephrectomy. Results showed
that the dichotomous CCR7 expression associated
with TNM stage at initial diagnosis (P = 0.004), lymph
node involvement (P = 0.031) and marginally with
histology (P = 0.086) and number of metastatic sites
(P = 0.070). It also correlated with patients’ best re-
sponse of TKIs (P < 0.001).
Impact of baseline characteristics, including dichotomous
CCR7 expression, on OS in mRCC patients receiving TKIs
Within this cohort, 64.5% (71/110) patients died
during the follow-up and the median OS was
23.5 months. Kaplan-Meier analysis revealed that pa-
tients with high CCR7 expression had a significantly
poorer OS (P < 0.001 after correction) (Fig. 1a). Uni-
variate analysis confirmed this significance (P < 0.001)
(Additional file 2: Table S1). Multivariate Cox analysis
was further performed and suggested high CCR7 ex-
pression as an independent adverse prognostic factor
for mRCC patients’ OS prediction (HR 2.256, 95% CI
1.336–3.809, P = 0.002; P = 0.003 after 1000 bootstrap),
together with tumor histology and Heng’s risk group
(Table 2). Lung and lymph node involvement were
excluded from the model for being potential con-
founding factors for number of metastatic sites.
Stratified analysis were further performed, and we
found that CCR7 expression could discriminate most pa-
tient groups’ overall survival except those in the non-
clear cell type or Heng’s risk favorable/poor groups
(Additional file 3: Table S2). But after incorporating
the high/low CCR7 expression directly into Heng’s
risk to form a new model, the OS between different
groups displayed vigorously discriminative consequences
(P < 0.001) (Fig. 1b). Furthermore, ROC analysis was car-
ried out at the time of 12 and 24-month follow-up, and
the new model showed better prognostic power than
using Heng’s risk model alone in both the ccRCC and
all patient groups (Fig. 2). Incorporating CCR7 IOD
score as a continuous variable also displayed similar
results (Additional file 4: Figure S2).
Impact of baseline characteristics, including dichotomous
CCR7 expression, on PFS in mRCC patients receiving TKIs
During the follow-up period, 85.0% (91/107) patients have
developed disease progression. The median PFS was
9.8 months. Patients’ best response and its correlation
with CCR7 were shown in Table 1. Figure 3a revealed that
RCC in the PD group displayed a significantly higher
CCR7 expression compared to partial response (PR) and
stable disease (SD) groups. Kaplan-Meier analysis sug-
gested an adverse predictive effect of high CCR7 expres-
sion in patients receiving TKIs (P = 0.001 after correction)
(Fig. 3b) and was also confirmed in a multivariate model
(HR 1.835, 95% CI 1.156–2.912, P = 0.010; P = 0.013 after
1000 bootstrap) (Table 2). After incorporating CCR7 into
the Heng’s model, patients in the new model
Fig. 1 Impact of tumoral CCR7 expression on patients’ overall survival (OS). a OS according to tumoral CCR7 expression; b Heng’s risk model
expanded with tumoral CCR7 expression
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displayed significant PFS divergence between different
groups (P < 0.001) (Fig. 3c). Since the Heng’s risk cri-
teria was initially designed for OS prediction, further ROC
comparison was not performed.
CCR7 expression and its correlation with lymph node
involvement
In Fig. 4a, the CCR7 IOD score of mRCC patients with
different baseline metastatic sites were plotted, and re-
vealed a potential higher expression of CCR7 in patients
with baseline lymph node metastasis, in accordance with
the χ2 test in Table 1, though the Kruskal-Wallis test did
not meet statistical significance (P = 0.083). For explor-
ing the possible impact of CCR7 on lymphatic invasion
during the drug treatment period, we found that four
patients within this cohort have developed disease pro-
gression due to new lymph node lesions development,
and all their tumor samples displayed CCR7 high ex-
pression (Fig. 4b).
Discussion
CCR7 was naturally a homeostatic chemokine receptor
expressed on various subtypes of immune cells encom-
passing T cells, B cells, natural killer cells and dendritic
cells, enabling them to circulate through the CCL-19/21
positive lymphatic highways [7]. Its expression on cancer
cells was first recognized on hematogenous malignancies,
in which the connection between high CCR7 expression
and lymphoid organ involvement was discovered [21].
Subsequently, numerous laboratory studies confirmed this
pro-invasion, mostly pro-lymph vessel metastatic function
in various cancer types, including breast cancer, melan-
oma, non-small cell lung cancer, prostate cancer, head-
and-neck cancer and gastrointestinal cancer [9]. Here, our
results suggested that CCR7 also expressed on several
RCC specimens and associated with various patient base-
line characteristics (Table 1, Additional file 1: Figure S1).
The clinical prognostic value of CCR7 has been stud-
ied in several other cancer types. In a meta-analysis in-
cluding 1697 gastric cancer patients, high CCR7
correlated with a worse 5-year overall survival rate [22].
Studies in melanoma and colorectal cancer also dis-
played similar results [23, 24]. In this study, we have
found that high CCR7 staining intensity could be used
as an adverse prognosticator for mRCC patients’ overall
survival. Moreover, a new model integrating CCR7
expression into Heng’s risk criteria performed better
than using Heng’s risk alone, and the adding prognostic
value mostly came from the intermediate patient groups
(Additional file 3: Table S2, Fig. 2a and b). This indicated
Fig. 2 ROC analysis of Heng’s risk model alone and expanded with CCR7 expression on patients’ OS. a all patients at 12 months; b all patients at
24 months; c pathologic clear cell type at 12 months; d pathologic clear cell type at 24 months
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that a substantial number of patients might switch be-
tween risk groups with a consequence for choice of
treatment strategy after CCR7 status was considered.
ROC analysis for the ccRCC patient group were also car-
ried out, considering the poor performance of CCR7 in
non-ccRCC patients (Fig. 2c and d).
For PFS analysis, to our knowledge, this study was the
first to report an association between tumoral CCR7 ex-
pression and PFS in mRCC patients following TKIs. As
the most widely used systemic therapy at present, TKI
drugs only reached ORRs for about 30% for mRCC pa-
tients, and the theories of drug resistance was complicated
[25]. It is increasingly evident that in some tumors, in
which angiogenesis is thwarted genetically or pharmaco-
logically, cancer cells could adapt by migrating more ag-
gressively into normal tissue, based on several pre-existing
invasion programmes such as epithelial-mesenchymal
transition (EMT) and MMP2/MMP9 secretion [26, 27], or
by switching on several distinctive programmes which
were currently unknown [28]. Since the CCR7 mediated
lymphatic specific migration and metastasis was also
based on several above mentioned programmes [8, 29],
and as a molecule which could give tumor itself survival
signal besides [30], we hypothesized that CCR7 positive
RCC cells might have a potential to migrate into the adja-
cent lymphatic tissue for survival after TKI drugs adminis-
tration, subsequently leading to resistance and disease
progression. As a result, our study did identify an inde-
pendent significant adverse predictive effect of high CCR7
expression on mRCC patients’ PFS (Fig. 3b) and its associ-
ation with poorer best drug response (Table 1, Fig. 3a).
Patients’ baseline lymph node involvement status was also
correlated (Table 1, Fig. 4a) and four patients who devel-
oped PD due to new lymph node metastasis all repre-
sented high CCR7 staining for their tumor tissues. All
these results above indicated an impact of tumoral CCR7
expression on patients’ PFS and lymphatic involvement
status, making this molecule a potential predictor for
mRCC patients receiving TKIs.
The major limitations of this pilot study were its retro-
spective design and relatively small sample size, with pa-
tients from a single center and same ethnic background.
Although central patient data review and bootstrap val-
idation were performed for minimizing inter-observer
and over-fitting bias, further external prospective valida-
tions were required, and related basic researches were
Fig. 3 Impact of tumoral CCR7 expression on patients’ best drug response for tyrosine kinase inhibitors and PFS. a Patients’ best drug response
according to tumoral CCR7 expression; b PFS according to tumoral CCR7 expression; c Heng’s risk model expanded with tumoral CCR7 expression
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needed for verifying our hypothesis. Samples from the
metastatic site after TKI therapies might be excellent
candidates for in-depth investigation. Besides, although
we took two cores and six scans from each patient’s
sample, intratumoral heterogeneity still might confound
the results. Patients in this study received sunitinib or
sorafenib as first-line therapy because other agents were
not available in China at that time, and other VEGF-
based TKI drugs such as pazopanib, axitinib and cabo-
zantinib should also be taken into further consideration.
Conclusions
Our study indicated that high tumoral CCR7 expression
correlated with potential lymphatic involvement and
poor prognosis in mRCC patients treated with TKIs.
This biomarker could also be combined with the Heng’s
risk model for better risk stratification.
Additional files
Additional file 1: Figure S1. Representative photographs of CCR7
immunostaining and cut-off point choosing. (A) Tumoral CCR7 low ex-
pression; (B) Tumoral CCR7 high expression; (C) Peritumoral CCR7 expres-
sion. Original magnification × 200; (D), (F) Smooth estimates of HR (+1
IOD) showed a higher risk of death and progression for patients with
stronger tumoral CCR7 staining; (E), (G) Smooth estimates of HR (using
IOD = 215 as a reference) showed a significant and stable prognostic
difference between patients with high/low tumoral CCR7 staining.
Dashed lines: 95% confidence bands. (TIF 5423 kb)
Additional file 2: Table S1.Univariate analyses of characteristics
associated with overall survival and progression free survival. (DOCX 69 kb)
Additional file 3: Table S2.Hazard ratios for OS and PFS based on CCR7
in different subgroups (High vs Low). (DOCX 63 kb)
Additional file 4: Figure S2.ROC analysis of Heng’s risk model alone and
expanded with CCR7 continuous IOD score on patients’ OS. (A) all patients
at 12 months; (B) all patients at 24 months; (C) pathologic clear cell type at
12 months; (D) pathologic clear cell type at 24 months. (TIF 1371 kb)
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OS: Overall survival; PD: Progressive disease; PFS: Progression free survival;
RCC: Renal cell carcinoma; ROC: Receiver operating characteristic;
TKI: Tyrosine kinase inhibitor
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